2025
FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniques.
Payabvash S, Sharaf K, Zeevi T, Gross M, Mahajan A, Kann B, Judson B, Schreier A, Krenn J, Prasad M, Burtness B, Aboian M, Canis M, Baumeister P, Reichel C, Haider S. FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniques. American Journal Of Neuroradiology 2025, ajnr.a8836. PMID: 40379456, DOI: 10.3174/ajnr.a8836.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaStandardized uptake valueSquamous cell carcinomaFDG-PETRadiomic featuresPET featuresOncological outcomesLentiform nucleusCell carcinomaUptake valuePrognostic value of radiomics featuresC-indexOropharyngeal squamous cell carcinoma patientsValue of radiomic featuresProgression-free survivalOropharyngeal cancer patientsUnivariate Cox regression modelPredicting oncological outcomesRandom survival forestArea under the curveHarrell's concordance indexIndividual radiomics featuresStandardized uptake ratioHarrell's C-indexCox regression modelsModeling inter‐reader variability in clinical target volume delineation for soft tissue sarcomas using diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Beddok A, Rozenblum L, Moteabbed M, Grogg K, Xing F, Woo J, Chen Y, Lim R, Liu X, Ma C, Fakhri G. Modeling inter‐reader variability in clinical target volume delineation for soft tissue sarcomas using diffusion model. Medical Physics 2025 PMID: 40317577, DOI: 10.1002/mp.17865.Peer-Reviewed Original ResearchClinical target volumeGross tumor volumeClinical target volume delineationSoft tissue sarcomasInter-reader variabilityTissue sarcomasClinical target volume contoursMagnetic resonance imagingCTV delineationTarget volume delineationComputed tomographyTreatment of soft tissue sarcomasFluorodeoxyglucose positron emission tomographyCTV contoursTarget volumeVolume delineationT1-weighted magnetic resonance imagingRadiotherapy treatmentEnergy distanceHigh Dice indexPositron emission tomographyTumor volumeMicroscopic spreadFDG-PETTreatment planningGross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model
Dong Y, Marin T, Zhuo Y, Najem E, Moteabbed M, Xing F, Beddok A, Lahoud R, Rozenblum L, Ding Z, Liu X, Grogg K, Woo J, Chen Y, Lim R, Ma C, Fakhri G. Gross tumor volume confidence maps prediction for soft tissue sarcomas from multi-modality medical images using a diffusion model. Physics And Imaging In Radiation Oncology 2025, 33: 100734. PMID: 40123775, PMCID: PMC11926426, DOI: 10.1016/j.phro.2025.100734.Peer-Reviewed Original ResearchGross tumor volumeSoft tissue sarcomasTissue sarcomasGross tumor volume delineationManual GTV delineationsMagnetic resonance imagingComputed tomographyFluorodeoxyglucose positron emission tomographyGTV delineationT1-weighted magnetic resonance imagingSingle-modePositron emission tomographyMulti-modal medical imagesTumor volumeIntra-reader variabilityFDG-PETTreatment planningSarcomaEmission tomographyImaging modalitiesResonance imagingDiffusion modelDice indexReader variabilityPatients
2024
BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES. Neuro-Oncology 2024, 26: viii38-viii38. PMCID: PMC11552887, DOI: 10.1093/neuonc/noae165.0151.Peer-Reviewed Original ResearchPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETRituximab-based therapyRituximab-based treatmentMedian overall survivalNon-Hodgkin's lymphomaManifestation of malignancyNervous systemTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseSystematic reviewProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationClinical presentationNIMG-32. ORAL ADMINISTRATION OF DEUTERATED CHOLINE AS A NEW APPROACH TO PROVIDE HIGH TUMOR-TO-BRAIN IMAGE CONTRAST IN DEUTERIUM METABOLIC IMAGING (DMI)
Osoliniec V, Thomas M, de Graaf R, De Feyter H. NIMG-32. ORAL ADMINISTRATION OF DEUTERATED CHOLINE AS A NEW APPROACH TO PROVIDE HIGH TUMOR-TO-BRAIN IMAGE CONTRAST IN DEUTERIUM METABOLIC IMAGING (DMI). Neuro-Oncology 2024, 26: viii202-viii202. PMCID: PMC11552881, DOI: 10.1093/neuonc/noae165.0797.Peer-Reviewed Original ResearchTumor-to-brain contrastOral administrationMetabolic imagingDeuterium metabolic imagingIV infusionTCho concentrationOrthotopic models of glioblastomaNormal brainContralateral normal brainTumor-to-brainDays of oral administrationModels of glioblastomaAdministration of cholineTesla MRI scannerTCho signalMg/kg body weightOrthotopic modelFDG-PETOral administration of cholineTotal cholineDaily doseIntravenous infusionF344 ratsTail veinCholine metabolitesNIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancementP27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Huttner A, Fulbright R, Baehring J, Kaulen L. P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS. Neuro-Oncology 2024, 26: v138-v139. PMCID: PMC11485484, DOI: 10.1093/neuonc/noae144.472.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemNerve root lesionsDiagnostic intervalRelapse of NHLSymptom onsetAssociated with early diagnosisTertiary referral centerAtypical clinical presentationRoot lesionsCerebrospinal fluid examinationDiagnostic work-upYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyClinical presentationReferral centerFluid examinationQuality control databaseDiagnostic delayFDG-PETPrimary diseaseUnivariate analysisConventional CTNeurolymphomatosis6421 Imaging Phenotype May Predict Genotype In Human Pheochromocytoma: Relationships Between Genetic Mutation Clusters, Metabolite Transporter Expression, And Radiotracer Uptake
Sakuma I, Fujimoto M, Vatner D, Yokote K, Tanaka T. 6421 Imaging Phenotype May Predict Genotype In Human Pheochromocytoma: Relationships Between Genetic Mutation Clusters, Metabolite Transporter Expression, And Radiotracer Uptake. Journal Of The Endocrine Society 2024, 8: bvae163.210. PMCID: PMC11455308, DOI: 10.1210/jendso/bvae163.210.Peer-Reviewed Original ResearchGATA binding protein 3Expression of norepinephrine transporterGlucose transporter 1Chromaffin cell differentiationNorepinephrine transporter expressionNorepinephrine transporterFDG-PETGlucocorticoid receptorCluster 1 mutationsRadiotracer uptakeLevels of norepinephrine transportersGlucose transporter 1 expressionLocalization of pheochromocytomaChromaffin cell phenotypeCluster 2 tumorsExpression of glucose transporter 1Binding protein-3Expression levelsTumor gene expressionNorepinephrine transporter geneLevels of glucose transporter 1Cell differentiationTranscription factor Phox2aPositron emission tomographyFDG avidityClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationRelationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study
Cayir S, Volpi T, Toyonaga T, Gallezot J, Yang Y, Sadabad F, Mulnix T, Mecca A, Fesharaki‐Zadeh A, Matuskey D. Relationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study. Journal Of Neuroimaging 2024, 34: 627-634. PMID: 38676301, PMCID: PMC11511789, DOI: 10.1111/jon.13206.Peer-Reviewed Original ResearchMoCA scoresFDG-PETAssociation of cognitionStandardized uptake value ratioMontreal Cognitive AssessmentSignificant positive associationFrontotemporal dementiaPrimary outcome measurePosterior cingulate cortexDecline of cognitive functionYears of ageGM volumeFrontal cortexOutcome measuresCognitive dysfunctionGray matterCognitive AssessmentMoCAAssociated with cognitive dysfunctionFluorodeoxyglucose (FDG)-PETPositive associationMagnetic resonance imagingPartial volume correctionCognitive functionDementia
2023
Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort
de Geus M, Leslie S, Wang W, Lam T, Broekman M, Neefjes S, Nairn A, Carlyle B, Arnold S. Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.078466.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentHospital neurology serviceNon-AD diagnosesDiagnostic lumbar puncturePrognosis of ADCerebrospinal fluid biomarkersClinic cohortFurther mechanistic studiesNeurology serviceFDG-PETBrain metabolismFluid biomarkersLumbar puncturePatient cohortClinical indicationsDisease progressionATN biomarkersClinical cohortTreatment responseComplex cohortBackground DiagnosisCSF samplesTreatment efficacyLinear regression analysis
2022
P11.54.A Factors effecting early diagnosis in neurolymphomatosis
Egert A, Karschnia P, Huttner A, Baehring J, Kaulen L. P11.54.A Factors effecting early diagnosis in neurolymphomatosis. Neuro-Oncology 2022, 24: ii70-ii70. PMCID: PMC9443184, DOI: 10.1093/neuonc/noac174.243.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly diagnosisSymptom onsetPathological findingsDiffuse large B-cell lymphomaCase of neurolymphomatosisDiagnosis of neurolymphomatosisYale Cancer CenterTertiary referral centerFDG-PET imagingPeripheral nervous systemB-cell lymphomaImaging gold standardSPSS version 27Painful polyneuropathyPainless polyneuropathySecondary neurolymphomatosisAutonomic neuropathyCranial neuropathiesMedian intervalReferral centerAutonomic nervesClinical suspicionFDG-PETCancer CenterFull automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
Jemaa S, Paulson J, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano R, El-Galaly T, Nielsen T, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022, 22: 39. PMID: 35962459, PMCID: PMC9373298, DOI: 10.1186/s40644-022-00476-0.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaProgression-free survivalOverall survivalFDG-PETUntreated diffuse large B-cell lymphomaHazard ratioHigh-risk DLBCL patientsCentral nervous system relapseLarge B-cell lymphomaMetabolic tumor volumeImaging-based risk factorsB-cell lymphomaEnhanced risk stratificationHigh-risk populationImaging metricsRisk increaseDLBCL patientsFDG-PET/CTSystemic relapseTumor volumeOrgan involvementPrognostic improvementRisk stratificationInvasive proceduresClinical dataThe role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review
Carlson B, Harmath C, Turaga K, Kindler H, Armato S, Straus C. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdominal Radiology 2022, 47: 1725-1740. PMID: 35257201, DOI: 10.1007/s00261-022-03464-x.Peer-Reviewed Original ResearchConceptsMaximum tumor dimensionMalignant peritoneal mesotheliomaMagnetic resonance imagingImaging modalitiesTumor dimensionPeritoneal mesotheliomaFluorodeoxyglucose positron emission tomographyPeritoneal carcinomatosis indexPleural plaquesSystematic reviewPositron emission tomographyPeritoneal carcinomatosisPeritoneal thickeningPeritoneal diseaseSystematic review of original research articlesReview of original research articlesFDG-PETClinical efficacyPoor prognosisImaging ReportingMesenteric thickeningDiagnostic sensitivityImaging studiesImaging protocolEmission tomography
2021
Generation of parametric Ki images for FDG PET using two 5‐min scans
Wu J, Liu H, Ye Q, Gallezot J, Naganawa M, Miao T, Lu Y, Chen M, Esserman DA, Kyriakides TC, Carson RE, Liu C. Generation of parametric Ki images for FDG PET using two 5‐min scans. Medical Physics 2021, 48: 5219-5231. PMID: 34287939, DOI: 10.1002/mp.15113.Peer-Reviewed Original ResearchConceptsPopulation-based input functionDynamic FDG-PET scansFDG-PET scansFDG-PETSUV changesPET scansClinical practiceSolid lung nodulesClinical usefulnessLate scansBone marrowRegion of interestLung nodulesInput functionScansPatlak analysisKi imagesMin/T-testCorrelation coefficientTumorsSubjectsNodulesDynamic imagingPETComparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease
Mayblyum D, Becker J, Jacobs H, Buckley R, Schultz A, Sepulcre J, Sanchez J, Rubinstein Z, Katz S, Moody K, Vannini P, Papp K, Rentz D, Price J, Sperling R, Johnson K, Hanseeuw B. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology 2021, 96: e2933-e2943. PMID: 33952655, PMCID: PMC8253562, DOI: 10.1212/wnl.0000000000012108.Peer-Reviewed Original ResearchPreclinical Alzheimer's diseaseCognitive declineHarvard Aging Brain StudyPreclinical Alzheimer Cognitive CompositePrevention trialsAlzheimer's diseaseAging Brain StudyClinically normal adultsPittsburgh compound B (PiB)-PETProspective cohort studyClass II evidenceCompound B (PiB)-PETCognitive compositeIsthmus cingulateIncrease of statistical powerStructural MRICognitive evaluationBackward stepwise regressionEntorhinal cortexHigher amyloidFDG-PETBrain studiesLinear mixed-effects modelsFollow-upCohort study
2020
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.Peer-Reviewed Original ResearchConceptsLocally advanced nasopharyngeal carcinomaAdvanced nasopharyngeal carcinomaNasopharyngeal carcinomaConcurrent chemoradiationGemcitabine chemotherapyArm CIncreased immune cell infiltrationComplete metabolic responsePosttreatment tumor biopsiesAnti-VEGF therapyArm A patientsRelapse-free survivalMetastatic nasopharyngeal carcinomaImmune cell infiltrationImmune cell traffickingVEGF axisTumor responseInduction cisplatinAntiangiogenic therapyTumor biopsiesTumor perfusionA patientsFDG-PETPericyte coverageStandard treatmentSpeckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis
Barssoum K, Altibi A, Rai D, Kumar A, Kharsa A, Chowdhury M, Thakkar S, Shahid S, Abdelazeem M, Abuzaid A, Baibhav B, Parikh V, Feitell S, Balmer‐Swain M, Rao M, Amsallem M, Nanda N. Speckle tracking echocardiography can predict subclinical myocardial involvement in patients with sarcoidosis: A meta‐analysis. Echocardiography 2020, 37: 2061-2070. PMID: 33058271, DOI: 10.1111/echo.14886.Peer-Reviewed Original ResearchConceptsLeft ventricular global longitudinal strainGlobal circumferential strainSpeckle tracking echocardiographyStandardized mean differenceCardiac sarcoidosisCardiac magnetic resonanceSarcoidosis groupTracking echocardiographyHealthy controlsConfidence intervalsExtra-cardiac sarcoidosisGlobal longitudinal strainSubclinical myocardial involvementMeta-analysisScreening of CSAdvanced imaging modalitiesRandom-effects modelEnglish-language articlesPositron emission tomographyMyocardial involvementSarcoidosis patientsCardiac symptomsFDG-PETLongitudinal strainEchocardiographyPET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma
Haider SP, Mahajan A, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kucukkaya AS, Kann BH, Judson BL, Prasad ML, Burtness B, Payabvash S. PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2978-2991. PMID: 32399621, DOI: 10.1007/s00259-020-04839-2.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaMetastatic cervical lymph nodesCervical lymph nodesLymph nodesSquamous cell carcinomaPrimary tumorPET/CTHPV associationCell carcinomaRadiomics signatureVolume of interestHuman papilloma virus associationHuman papillomavirus associationMulti-national cohortNon-contrast CTHPV statusFDG-PETExternal cohortVirus associationFinal modelTumorsRadiomic featuresCTSignificant differencesLesion featuresA First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research 2020, 26: 1229-1236. PMID: 31848189, DOI: 10.1158/1078-0432.ccr-19-2574.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDose-Response Relationship, DrugFatigueFemaleHumansMaleMAP Kinase Signaling SystemMaximum Tolerated DoseMiddle AgedMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NauseaNeoplasmsPatient SafetyProtein Kinase InhibitorsPyridonesPyrimidinesTissue DistributionVomitingConceptsBRAF-mutant colorectal cancerColorectal cancerAdverse eventsFDG-PETCommon drug-related adverse eventsSolid tumorsDrug-related adverse eventsPhase IPartial metabolic responseAcceptable safety profileAdvanced solid tumorsDose-proportional increaseGrade 3 rashMetastatic solid tumorsSerial tumor biopsiesSingle-agent activityBest overall responseHuman phase IMAPK pathway inhibitionMultiple tumor typesStable diseaseEscalation studyPartial responseOral inhibitorPharmacodynamic effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply